Advertisement

Topics

Midatech Group Ltd. Company Profile

08:24 EDT 26th September 2018 | BioPortfolio

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications for a number of industry segments including life sciences, electronics and fine chemicals.

Founded in 2000, Midatech Ltd is a private company headquartered in Abingdon, Oxford, UK. In 2005, it registered its manufacturing facility – Midatech Biogune S.L. – in Bilbao, Spain, which became fully operational for cGMP standard design and manufacturing of API nanoparticles in March 2007. In 2008, Midatech Ltd further expanded with the opening of PharMida AG in Basel, Switzerland, which is responsible for clinical development of Midatech’s products.

Midatech’s biocompatible nanoparticles possess a number of unique properties that make them ideal for diagnostic and therapeutic applications. The nanoparticles are water dispersible and can be designed to diffuse freely in vivo, or to target specific cells. With a diameter of less than five nm, unbound nanoparticles are rapidly excreted by the kidneys, and thereby reduce the likelihood of non-specific in vivo accumulation. Their small size potentially enables drug delivery via different routes of administration, including parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation. Furthermore, their high-degree of stability to enzymatic digestion makes them attractive for oral administration. The nanoparticles can be designed to attaching multiple ligands to the nanoparticle surface, thereby allowing multivalent drug or multi-drug delivery on a single particle. Owing to the fact that the nanoparticles self-assemble in a single synthetic step, commercial manufacturing is straightforward, safe, scalable and low cost.

Midatech Ltd. has exclusive world-wide IP for the technology covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas as well as in other industries. It also has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles.
 

Location

4 & 5 Dunmore Court
Wootton Road
Abingdon
Oxfordshire
OX13 6BH
UK

Contact

Phone: +44 1235 528 022
Fax: + 44 1235 528 023
Email: info@midatechgroup.com


News Articles [657 Associated News Articles listed on BioPortfolio]

Midatech: The Story of a Nanoparticle Start-Up

In this exclusive interview, Fintan Walton talks to Tom Rademacher, President of Midatech, about the formation of the biotech, Professor Rademacher's fifth start-up company. Tom discusses Midatech's b...

Strong sales ''a good validation'' for Midatech Pharma Plc's entry into the US

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) reported a tenfold year-on-year increase in revenue in the first half of 2016. Much of the increase was down to the group's acquisition of  cancer s...

Midatech Pharma says revenue rose 37% in first half

“I am pleased to report that Midatech's US commercial business has continued to grow strongly in 2017"

Midatech Pharma to co-promote Bausch Health's NeutraSal in the US

Bausch Health Companies Inc. (formerly Valeant) is licensing Midatech Pharma PLC’s Midatech Pharma US Inc. subsidiary exclusive rights to promote its supersaturated calcium product NeutraSal rinse i...

Zak Mir: Midatech Pharma looking upwards if it breaks 50-day trend

Midatech Pharma Inc (LON:MTPH) can look towards 118p if it can break through the 50-day moving average suggests technical analyst Zak Mir.

Midatech Pharma to start first-in-man trials of potential new treatment for a childhood brain cancer

Dosing has begun using Midatech’s MTX110 in patients with diffuse intrinsic pontine glioma (DIPG), a highly aggressive strain of the disease

New loan for Midatech promises greater profitability

Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising...

Midatech Pharma starts dosing of sustained release tumour treatment in equivalence study

Midatech wants to demonstrate that Q-Octreotide can achieve safe and effective growth hormone levels while also highlighting the advantages of its release system

PubMed Articles [1729 Associated PubMed Articles listed on BioPortfolio]

Group Influences on Engaging Self-Control: Children Delay Gratification and Value It More When Their In-Group Delays and Their Out-Group Doesn't.

Self-control emerges in a rich sociocultural context. Do group norms around self-control influence the degree to which children use it? We tested this possibility by assigning 3- to 5-year-old childre...

Does Timing of Surgery Affect Treatment of the Terrible Triad of the Elbow?

BACKGROUND This study investigated the influence of surgical timing on the treatment of terrible triad of the elbow (TTE). MATERIAL AND METHODS After exclusion, 63 patients were enrolled in this study...

An Examination of Group Size and Valence in Delay Discounting of Shared Outcomes.

Previous research has examined delay discounting in a group context, where the outcomes are shared with others. These studies indicate shallow delay discounting in a group context compared to an indiv...

Ameliorating effects of tempol on methotrexate-induced liver injury in rats.

Methotrexate (MTX) is used in the treatment of certain types of cancers and chronic inflammatory illnesses, although the clinical use of MTX is limited due to its adverse effects, the most common of w...

Nephroprotective Effect of Zingerone against CCl-Induced Renal Toxicity in Swiss Albino Mice: Molecular Mechanism.

The protective effects of Zingerone against CCl induced nephrotoxicity in Swiss albino mice via modulation of metabolizing enzyme, oxidative stress, inflammatory cytokines, and apoptosis. The biochemi...

Clinical Trials [3922 Associated Clinical Trials listed on BioPortfolio]

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Ultrasound and Exercises in Knee Osteoarthritis

The aim of this investigation is to compare the effects of continuous (CUS) and pulsed (PUS) ultrasound associated with a program of exercises on pain, range of motion, muscle strength, fu...

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

Companies [1631 Associated Companies listed on BioPortfolio]

Midatech Ltd.

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products w...

Midatech Group Ltd.

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel character...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Midatech Group Ltd." on BioPortfolio

We have published hundreds of Midatech Group Ltd. news stories on BioPortfolio along with dozens of Midatech Group Ltd. Clinical Trials and PubMed Articles about Midatech Group Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Midatech Group Ltd. Companies in our database. You can also find out about relevant Midatech Group Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record